NCT02236572 - Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2014

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions

Breast Cancer

Interventions

DRUG

Everolimus

"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"

Trial Locations (1)

06520

Yale University, New Haven